Condition: Solid Tumor · Sponsor: Sumitomo Pharma America, Inc.
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
This description comes directly from the study's public registry record.
Eileen Maunsell · 774-405-5069 · eileen.maunsell@us.sumitomo-pharma.com
Shuichi Iino · 508-481-6700 · shuichi.iino@us.sumitomo-pharma.com
Always discuss trial participation with your own doctor first.
| Cedars Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Sarah Cannon Research Institute at HealthOne | Denver, Colorado, United States | Recruiting |
| Northwestern Medicine Cancer Center | Chicago, Illinois, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
| National Cancer Center Hospital East | Kashiwa-shi, Japan | Recruiting |
| Kyoto University Hospital | Kyoto, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06526819